In addition, they performed comprehensive assays to determine the regulatory role of RANK/RANKL in the development of breast cancer, indicating a crucial role for RANK/RANKL signaling in tumor initiation and providing a research direction and robust support for the anti-RANKL clinical studies, such as denosumab, in the treatment of breast cancer. This evidence concerns the gene TNFRSF11A and breast cancer.